HWM
CPRX

Hemington Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Hemington Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$0 Sell
2
-2
-50% -$41 ﹤0.01% 1563
2025
Q2 		$0 Hold
4
– – ﹤0.01% 1540
2025
Q1 		$0 Hold
4
– – ﹤0.01% 1543
2024
Q4 		$0 Buy
4
+2
+100% +$43 ﹤0.01% 1582
2024
Q3 		$0 Buy
+2
New +$37 ﹤0.01% 1526

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hemington Wealth Management's CPRX Position: Q3 2025 in Review

Hemington Wealth Management reduced its Catalyst Pharmaceutical (CPRX) stake by 50% in Q3 2025, selling an estimated $41 and leaving 2 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1563.

Hemington Wealth Management first reported a position in CPRX in Q3 2024 and has held it in 5 quarters since. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • Hemington Wealth Management held 2 shares of Catalyst Pharmaceutical worth $0 as of Q3 2025.
  • Hemington Wealth Management sold 2 Catalyst Pharmaceutical shares in Q3 2025, an estimated $41.
  • Catalyst Pharmaceutical made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #1563 holding.
  • Hemington Wealth Management first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 5 quarters since.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.